单药单片低剂量三联疗法对比标准剂量单药治疗轻中度高血压
两项在韩国开展的III期双盲随机对照试验(HM-APOLLO-301和302)比较了单片复方超低剂量三联制剂LDC-ALC(氨氯地平1.67 mg/氯沙坦钾16.67 mg/氯噻酮4.17 mg)与标准剂量单药(氨氯地平5 mg或氯沙坦钾50 mg)治疗轻中度高血压的疗效与安全性。主要终点为第8周收缩压降幅。结果显示,LDC-ALC在降压效果上不劣于氨氯地平且与氯沙坦相比兼具优效性,短期耐受性相似。
要点
- LDC-ALC降压效果不劣于氨氯地平5 mg,第8周收缩压降幅相似。
- LDC-ALC降压效果优于氯沙坦50 mg,收缩压和舒张压降幅更大且血压控制率更高。
- LDC-ALC组不良事件发生率与单药组相似,因不良事件退出率≤1%,无严重药物相关事件。
核心结论
- 单片超低剂量三联复方LDC-ALC在轻中度高血压患者中降压效果不劣于氨氯地平单药且优于氯沙坦单药,短期耐受性良好,可作为初始治疗的有效替代选择。
研究设计与样本
- 两项多中心、随机、双盲、活性对照III期研究(HM-APOLLO-301和302)在韩国开展,纳入≥19岁、安慰剂洗脱4周后诊室收缩压140至<180 mm Hg且舒张压<110 mm Hg的轻中度高血压患者,随机接受8周治疗。
- 研究301比较LDC-ALC与氨氯地平5 mg;研究302比较LDC-ALC与氯沙坦钾50 mg。
- 主要终点为第8周收缩压降幅,先检验非劣效性再检验优效性。
主要发现
- 研究301:LDC-ALC对比氨氯地平,第8周收缩压降幅最小二乘均值变化为-19.1 vs -19.9 mm Hg(95%CI -1.5至3.1,P=0.495),达到非劣效(单侧97.5%CI上限2.8 mm Hg,<3 mm Hg非劣效界值),舒张压降幅和血压控制率相似。
- 研究302:LDC-ALC对比氯沙坦,第8周收缩压降幅最小二乘均值变化为-19.9 vs -16.4 mm Hg(95%CI -6.6至-0.2,P=0.037),既非劣(单侧97.5%CI上限-0.6 mm Hg)又优效,舒张压降幅更大且血压控制率更高。
- 不良事件发生率:研究301中LDC-ALC组11.7% vs 氨氯地平组13.9%;研究302中LDC-ALC组6.4% vs 氯沙坦组3.3%;因治疗退出率≤1%,无严重药物相关事件。
关键数值与推荐
- 研究301非劣效界值为收缩压降幅差异<3 mm Hg,LDC-ALC单侧97.5%CI上限为2.8 mm Hg。
- 研究302优效性检验P=0.037,收缩压降幅差异95%CI为-6.6至-0.2 mm Hg。
- LDC-ALC成分为氨氯地平1.67 mg、氯沙坦钾16.67 mg、氯噻酮4.17 mg;对照药为氨氯地平5 mg或氯沙坦钾50 mg;疗程8周。
临床怎么用
- 对于轻中度高血压患者,可考虑将单片超低剂量三联复方LDC-ALC作为初始治疗选择之一。
- LDC-ALC降压效果与氨氯地平5 mg相当且优于氯沙坦50 mg,短期耐受性良好,退出率低。
- 该研究支持在临床实践中扩大经过验证的初始降压策略,但需结合患者个体情况。
局限性
- 研究仅在韩国进行,结论外推至其他种族或地区需谨慎。
- 随访时间仅8周,缺乏长期心血管结局和安全性数据。
- 原文未报告对靶器官保护或长期依从性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-pill low-dose combination (LDC) antihypertensive therapy is an emerging strategy for improving blood pressure (BP) control. Although previous phase II and pragmatic studies suggested promise, these are the first phase III, double-blind, active-controlled trials comparing a single-pill ultra-low-dose triple combination with standard-dose monotherapy. OBJECTIVES: In these studies, we sought to compare a single-pill combination of 1.67 mg amlodipine, 16.67 mg losartan potassium, and 4.17 mg chlorthalidone (LDC-ALC) with standard-dose monotherapy-5 mg amlodipine or 50 mg losartan potassium-in patients with mild-to-moderate hypertension. METHODS: HM-APOLLO-301 (Study 301, May 2022-June 2023) and HM-APOLLO-302 (Study 302, March-December 2024) were multicenter, randomized, double-blind, active-controlled, phase III studies in South Korea. Study 301 compared LDC-ALC and amlodipine; Study 302 compared LDC-ALC and losartan. Adults (≥19 years of age) with systolic blood pressure (SBP) 140 to <180 mm Hg and diastolic blood pressure (DBP) <110 mm Hg after 4-week placebo run-in were randomized to 8 weeks of treatment. The primary endpoint was SBP reduction at week 8, assessed first for noninferiority, then for superiority. RESULTS: In Study 301, LDC-ALC exhibited noninferiority to amlodipine in reducing SBP at week 8 (upper bound of 1-sided 97.5% CI: 2.8 mm Hg [<3 mm Hg noninferiority margin]), and similar efficacy (least-squares mean change: -19.1 vs -19.9 mm Hg; 95% CI: -1.5 to 3.1; P = 0.495), with similar DBP reduction and blood pressure control rate. In Study 302, LDC-ALC was both noninferior (upper bound of one-sided 97.5% CI: -0.6 mm Hg) and superior to losartan (least-squares mean change: -19.9 vs -16.4 mm Hg; 95% CI: -6.6 to -0.2; P = 0.037) in SBP reduction at week 8, with greater DBP reduction and a higher blood pressure control rate than losartan. Adverse events were similar between groups (LDC-ALC vs amlodipine: 11.7% vs 13.9%; LDC-ALC vs losartan: 6.4% vs 3.3%), with ≤1% treatment withdrawals and no serious drug-related events. CONCLUSIONS: Single-pill LDC-ALC achieved BP reductions similar to those with amlodipine and greater than those with losartan monotherapy over 8 weeks, with similar short-term tolerability. These findings support LDC-ALC as an effective and well tolerated alternative initial therapy for mild-to-moderate hypertension, expanding the set of validated strategies alongside established monotherapies. (A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension [HM-APOLLO-301; NCT05362110]; A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension [HM-APOLLO-302, NCT06438172]).
引用
- Sung KC, Park K, Kim DH, et al. Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension. J Am Coll Cardiol. 2026. PMID: 41670573. doi:10.1016/j.jacc.2025.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。